A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Phase 2 Completed 4 enrolled Ophthotech Corporation

NaSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).

Timeline

Start: 2015-03-12
Primary completion: 2015-10-23
Completion: 2015-10-23

Publications

Park EJ, Choi J, Lee KC, Na DH. Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs. 2019 Jun;24(2):107-119. doi: 10.1080/14728214.2019.1604684. Epub 2019 Apr 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avacincaptad Pegol	Aptamer	1 mg	Intravitreal
Background	Aflibercept	Protein / enzyme biologic	2 mg	Intravitreal
Background	Bevacizumab	Monoclonal antibody	1.25 mg	Intravitreal
Background	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Indications

No indication recorded.